NCT05582434

Experience With Topical Acne Treatment

Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications

• Status: Active Not Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2

Conditions

• Acne

Interventions

Type	Name	Description
DRUG	clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel	Single topical treatment to be applied daily to area affected once daily.
DRUG	adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel	Two topical treatments to be applied to area affected once daily.
DRUG	Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel	Three topical treatments to be applied to area affected once daily.

Timeline

• Start date: 2024-02-15
• Primary completion: 2025-06-19
• Completion: 2026-11-01
• First posted: 2022-10-17
• Last updated: 2025-12-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study